Edition:
United States

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

37.20USD
4:00pm EDT
Change (% chg)

$-0.45 (-1.20%)
Prev Close
$37.65
Open
$37.40
Day's High
$37.83
Day's Low
$36.90
Volume
75,083
Avg. Vol
231,855
52-wk High
$51.00
52-wk Low
$26.98

Select another date:

Wed, Feb 28 2018

BRIEF-Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11

* PACIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Pacira Says FDA ‍committee ‍Did Not Reach A Unanimous Decision For Exparel As A Nerve Block To Produce Regional Analgesia​

* PACIRA PHARMACEUTICALS STATEMENT ON FDA ADVISORY COMMITTEE FOR EXPAREL® FOR USE AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA

BRIEF-Pacira Pharmaceuticals Says FDA Advisory Committee To Review SNDA For Exparel

* PACIRA PHARMACEUTICALS STOCK TRADING HALTED; FDA ADVISORY COMMITTEE TO REVIEW SNDA FOR EXPAREL® AS A NERVE BLOCK FOR REGIONAL ANALGESIA Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharma says FDA Posts Briefing Documents For Advisory Meeting Reviewing SNDA For Exparel

* PACIRA PHARMACEUTICALS INC - FDA POSTS BRIEFING DOCUMENTS FOR ADVISORY MEETING REVIEWING SNDA FOR EXPAREL AS A NERVE BLOCK FOR REGIONAL ANALGESIA

BRIEF-Wellstar And Pacira To Minimize Opioid Use Across Surgical Procedures

* WELLSTAR HEALTH SYSTEM AND PACIRA PHARMACEUTICALS ANNOUNCE PARTNERSHIP TO MINIMIZE OPIOID USE AND STANDARDIZE OUTCOMES ACROSS SURGICAL PROCEDURES Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharmaceuticals Reports Preliminary 2017 Revenues Of $286.6 Million

* PACIRA PHARMACEUTICALS REPORTS PRELIMINARY 2017 REVENUES OF $286.6 MILLION

Select another date: